Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

The magnitude of PSA decline was associated with improvement in clinical and patient-reported outcomes in patients with mCRPC receiving ¹⁷⁷Lu-PSMA-617 plus SoC in VISION. PSA decline therefore appears to have a prognostic value during ¹⁷⁷Lu-PSMA-617 treatment in this population.